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Abstract 
Background: HBV infection annually accounts for 1 million deaths worldwide as a result of cirrhosis, liver failure, and 
hepatocellular carcinoma. In addition to varying responses to antiviral therapy, HBV genotypes have also been shown 
to be associated with different pattern of disease progression. Despite a high HBV prevalence of >8 %, very few stud‑
ies have been carried out in Cameroon to determine the genotype distribution across the country. The aim of this 
study was to determine the prevalent genotypes, level of viraemia and correlate these parameters with liver enzymes 
known to be the most affordable and widely used biomarkers for monitoring disease progression in Cameroon.
Methods: This was a hospital‑community based study in which 81 participants who had been previously diagnosed 
of HBV were recruited and screened for HIV, HCV (for exclusion) and HBsAg for confirmation. Fifty known negative 
cases for HIV, HBV and HCV were tested and recruited to be used as healthy controls. Viral load and genotyping was 
performed only for HBV‑mono infected cases using the Abbott RealTime HBV automated m2000 system and INNO‑
LiPA HBV Genotyping assay respectively. Liver enzymes were measured by spectrophotometry on both hepatitis B 
positive and healthy control cases.
Results: The mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were significantly 
higher (p < 0.001) in HBV infected patients than “healthy controls”. Of the 81 HBV infected cases viral load was 
detected in 76 (93.8 %) with mean viral load of 120,807 IU/ml ± 440,159 SD. Mean viral load was significantly different 
in patients with abnormal AST and ALT when compared with patients who had normal ALT and AST. The identified 
genotypes in order of prevalence were A (47.4 %), E (39.5 %), C/E (3.9 %) A/C (2.6 %), A/E (2.6 %), B (1.3 %), A/B (1.3 %) 
and B/C (1.3 %).
Conclusion: Genotype E was significantly associated with higher mean viral load and mean AST levels. However, 
aminotransferase levels may not be a good marker for HBV disease progression as some patients could have nor‑
mal levels but still present with very high viral loads and therefore, remain active HBV infection with possible high 
transmission.
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Background
Hepatitis B virus (HBV) which is a global health prob-
lem, presents serological evidence of infection in 
approximately one-third of the world’s population with 
over 350–400 million people being chronic HBV sur-
face antigen (HBsAg) carriers [1]. Out of this number, 
65 million reside in Africa and this implies that Africa, 
with 12  % of the world’s population, carries approxi-
mately 18  % of the global burden of HBV infection 
[2]. In addition to the difficulties encountered in con-
trolling the spread of the disease, HBV still remains a 
health hazard partly because the virus exhibits different 
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genotypes and sub genotypes in different geographic 
regions of the world [3].
Several viral factors like HBV genotype, viral load and 
specific viral mutations have been associated with dis-
ease progression ranging from acute to chronic infection 
which may later on cause liver cirrhosis and subsequent 
Hepatocellular carcinoma (HCC). HBV genotypes are 
not only predictive of clinical outcomes but have also 
been associated with response to antiviral therapy [4], 
hepatitis B e antigen (HBeAg) sero-conversion rates and 
mutational patterns in the pre-core and core promoter 
regions [5].
HBV is classified into eight genotypes (A–H) based on 
a divergence in the entire nucleotide sequence >8 %. Fur-
thermore, on the basis of a >4 % but <8 % divergence in 
the complete nucleotide sequence, each genotype can be 
sub divided to sub genotypes [6]. The HBV genotypes are 
proving to be an invaluable tool in tracing the molecu-
lar evolution and patterns of spread of HBV. They show 
a distinct geographical distribution between and even 
within regions. Structural and functional differences 
between genotypes can influence the severity, likelihood 
of complications, HBeAg sero-conversion and response 
to vaccine and or treatment of HBV infection [7−9].
Concise studies have been carried out on the varying 
prevalence of HBV genotypes in North America, Asia, 
and Europe and even in some parts of Africa. Five HBV 
genotypes (A–E) have been identified in Africa with 
some particular genotypes predominantly found in some 
countries like genotype A in Kenya [10], genotype D in 
Tunisia [11], genotype A–D in South Africa [12] and 
genotype E in Nigeria [13]. However, Cameroon with an 
HBV prevalence rate >8 % [14] still does not have enough 
information on HBV genotypes prevalent across the 
country. This study seeks to determine the prevalence 
of HBV genotypes in the North West and South West 
regions of Cameroon and further investigate the influ-
ence of HBV genotypes on viral loads as has been shown 
in studies elsewhere [15].
An increase in HBV viral load may determine the 
degree of liver damage and subsequent development of 
HCC [16]. Alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) which are usually released 
into the blood circulation following liver cell damage are 
also used as markers for disease progression in Hepa-
titis [17]. This study also investigates the relationship 
between HBV viral load and serum aminotransferase 
levels. This comparison can be used to justify the valid-
ity of ALT/AST measurement as a single marker for HBV 
disease progression as is commonly used in developing 
countries like Cameroon. In addition, because ALT and 
AST released during HBV infection may be depend-
ent on HBV genotype, this study compares the effects of 
the different HBV genotypes identified on ALT and AST 
levels.
Methods
Study design, site and population
This was a hospital-community based cross-sectional 
study which enrolled participants who were 18  years of 
age and older. The Participants were enrolled from the 
Bamenda Regional hospital, Bamessing rural commu-
nity and St. Theresa Medical Centre, Mambu-Bafut of 
the North West region while in the South West region 
participants were enrolled from Buea Regional Hospital, 
Limbe Regional Hospital, Muyuka health district, Muea 
heath centre and Tiko. Some of the HBV positive partici-
pants had been previously diagnosed of HBV (using Dias-
pot strips which detect HBsAg) during a free screening 
community exercise that took place 8 months before this 
study. The other participants knew their status at least 
6 months before this study was conducted. These chronic 
HBV positive patients were screened again for HCV, 
HIV as well as HBV. Patients who showed HBV–HIV or 
HBV–HCV co-infection were excluded from the study. 
Fifty volunteers who were serologically negative for HIV, 
HBV and HCV were also enrolled from the South West 
region and used as “healthy controls” in the study. Prior 
to testing, the participants went through pre-test coun-
selling by competent HIV/AIDS counsellors.
Ethical considerations
The Cameroon National Ethics Committee (CNEC) 
in Yaoundé as well as the authorities in the concerned 
hospitals approved this study. Each participant signed a 
consent form at enrolment. For participants who were 
unable to read or understand the consent, a trained and 
competent counsellor verbally explained the information.
Sample collection and analysis
Approximately 10 ml of venous blood was collected (by 
a trained phlebotomist) in 2 separate 5  ml tubes (one 
containing EDTA and the other with no anticoagulant) 
from each participant using vacutainers. Samples with-
out EDTA were centrifuged at 1000g for 5 min and sera 
aliquoted. The sera was used for HBV, HCV and HIV 
screening using immuno-chromatographic tests (Dias-
pot, Acon® Laboratories Inc and Abbot Determine for 
HBsAg, HCV antibody and HIV antibody detection 
respectively) following manufacturer’s instructions. as 
well as for determining levels of AST and ALT [AST-
(GOT)-HBE06 and ALT-(GPT)-HBE07, Cypress Diag-
nostics Ltd.] by spectrophotometry (Mindray® BA-88 
Biochemistry analyser) following the manufacturer’s 
instructions. The liver enzyme tests were carried out on 
both hepatitis B positive and healthy control cases. The 
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EDTA samples were centrifuged, plasma aliquoted and 
shipped in dry ice to BioCollections Worldwide Inc; 
Miami, Florida, USA for HBV viral load and genotyping. 
Shipped plasma specimens were further screened as well 
for HBV, HCV and HIV using Genetic systems hepatitis 
B surface antigen enzyme immuno-assay (Bio-Rad Labo-
ratories, Washington DC, USA), Chiron RIBA HCV 3.0 
strip immuno-blot assay (Ortho Diagnostic Systems, New 
Jersey, USA) and GS Western blot (Bio-Rad Clinical diag-
nostics) respectively according to manufacturer’s instruc-
tions. This was done to confirm the previously acquired 
results obtained via the immunochromatographic tech-
niques. Viral load and genotyping was performed only 
for HBV-mono infected cases using the Abbott RealTime 
HBV automated m2000 system and INNO-LiPA HBV 
Genotyping assay respectively. We took into considera-
tion the identified shortcomings of using INNO-LiPA 
HBV Genotyping assay which could lead to overestima-
tion of mixed HBV genotypes [18].
Statistical analysis
Data was input into Microsoft Office Excel 2013 and 
analysed using SPSS for Windows version 17. Means of 
enzyme levels were compared with independent sample 
t test and the Chi-square test was used to compare cat-
egorical variables. Two sided p value < 0.05 was consid-
ered significant for all analysis.
Results
Demographic characteristic of patients and controls 
recruited in the study are shown on Table 1.
Comparison of AST and ALT levels in HBV cases and healthy 
controls
The mean alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) levels were significantly 
higher (p < 0.001) in HBV infected patients than healthy 
controls. However, these values (AST: 16.69  ±  6.88 
SD and ALT: 15.39 ±  7.08 SD) were significantly lower 
than upper limits of the test kits (AST  ≥  19  IU/ml, 
ALT ≥  22  IU/ml). After adjusting for age and sex, AST 
(p = 0.001) and ALT (p < 0.001) were still higher in HBV 
infected cases than controls (Table 2).
Generally, abnormal AST levels (M  >  19, F  >  16  IU/
ml) were common in HBV infected cases than controls 
(35.8 vs 10  %, p =  0.001). Similarly, abnormal (M  >  22, 
F > 18 IU/ml) ALT level was higher in infected cases than 
controls (17.3 vs 2 %, p = 0.008).
Viral load and genotype distribution
Of the 81 HBV infected cases viral load was detected in 
76 (93.8 %) with mean viral load of 120,807  IU/ml with 
a standard deviation (SD) of  ±  440,159  IU/ml (range 
14–2,664,237) while 5 (6.2  %) of the participants had 
undetectable viral load. Eleven (14.5  %) of the patients 
had viral load ≥20,000  IU/ml (mean 826,715 ± 901,130 
SD), while 65 (85.5  %) had viral load <20,000  IU/ml 
(mean 1345 ± 2775 SD).
Genotyping was performed on HBV patients with 
detectable viral load. The identified genotypes in order 
of prevalence were A (47.4  %), E (39.5  %), C/E (3.9  %) 
A/C (2.6  %), A/E (2.6  %), B (1.3  %), A/B (1.3  %) and 
B/C (1.3  %). Genotypes A and E were more prevalent 
(p = 0.034) in South West and North West region respec-
tively. Age and gender distribution across the predomi-
nant genotypes A and E are stated on Table 3. Amongst 
all the mixed genotype infections, only A/E was found in 
the North West Region of Cameroon (Table 4).
There was a significant difference in mean viral load of 
patients among the different genotypes (p = 0.031) with 
genotype E having the highest mean viral load. Male 
patients as well recorded a significantly higher mean viral 
load vis-à-vis female patients (p = 0.022) (Table 5). Simi-
larly, patients with elevated AST (p  =  0.002) and ALT 
(p < 0.001) levels had significantly higher viral loads than 
those with normal enzyme levels.
Table 1 Demographic characteristics of study participants (N = 131)
SD standard deviation
Characteristic Categories HBV positive cases, N = 81, n (%) Healthy control, N = 50, n (%)
Region North West 31 (38.3) –
South West 50 (61.7) 50 (100)
Sex Male 29 (35.8)
Mean age: 30.4 ± 9.8 SD
Median age: 27 years
30 (60)
Mean age: 41.5 ± 5.1 SD
Median age: 41 years
Female 52 (64.2)
Mean age: 31.9 ± 7.7 SD
Median age: 30 years
20 (40)
Mean age: 36.9 ± 9.8 SD
Median age: 39 years
Age group (years) <30 42 (51.9) 06 (12)
≥30 39 (48.1) 44 (88)
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Both mean AST and ALT levels were significantly 
higher in patients with viral load ≥20,000  IU/ml when 
compared to those with viral load levels <20,000  IU/ml. 
Likewise, AST levels were significantly higher in patients 
infected with genotype E when compared to A and oth-
ers (Table 6). Viral load correlated significantly with ALT 
(σ = 0.425, p < 0.01) and AST (σ = 0.272, p = 0.018).
Discussions
Genetic diversity of HBV and possible impact on disease 
progression, virulence and clinical outcome
HBV is a remarkable example of a virus that draws 
attention with its different genotypes (A–H) showing 
marked geographical distribution across the world. The 
investigation of genetic diversity of the viruses in differ-
ent locations is important, because variants may differ 
in their patterns of serologic reactivity, pathogenicity, 
virulence, and response to therapy [19]. Many studies 
conducted in the past have revealed genotype E predomi-
nance in West Africa. In this study, the most prevalent 
genotypes were A (47.4  %) and E (39.5  %). Genotype A 
(55.3 %) was more prevalent in South West while geno-
type E (55.2  %) was more prevalent in the North West 
region of Cameroon. Our finding alongside other simi-
lar findings of research conducted in different parts of 
Cameroon [20, 21, 22] may suggest that these genotypes 
(A and E) originated from this part of the world and are 
rapidly being transmitted here. In this study, Genotype E 
was even found in all the major areas were the patients 
resided (Table  4) indicating a wide distribution of the 
genotype in the North West and South West regions of 
Cameroon. The high prevalence of genotype A and E 
shows limited heterogeneity of HBV genotypes in Cam-
eroon and this may imply limited variations in the pro-
gression, clinical outcomes and antiviral therapy of HBV 
infections in Cameroon. As seen in other studies [23], 
mixed genotype infections were as well recorded in this 
study with 77.8  % (7/9) of such coming from the South 
West region. Genotype A/C and C/E were identified in 
patients from the same town or neighbouring towns 
(Buea and Tiko) in the South West Region (Table 4) sug-
gesting that these may be cases coming from a common 
Table 2 Comparison of mean ALT and AST levels between HBV infected cases and controls
SD standard deviation, SE standard error, AST aspartate aminotransferase, ALT alanine aminotransferase










p value Adjusted mean 
difference [SE]a
p value
AST 16.69 ± 6.88 12.78 ± 4.60 3.91 [1.10] 0.001 4.21 [1.19] 0.001
ALT 15.39 ± 7.08 9.94 ± 4.17 5.45 [1.10] < 0.001 5.69 [1.31] <0.001
Table 3 Gender and  age distribution among  genotype A 
and E infected persons
a Percentage within age group and within sex
Predominant genotypes (%)a p value
A E
Age group
<30 years 21 (60 %) 14 (40 %) 0.243
≥30 years 15 (48.4 %) 16 (51.6 %)
Gender
Male 11 (44 %) 14 (56 %) 0.138
Female 25 (61 %) 16 (39 %)
Table 4 Distribution of HBV genotype cases based on patient address
HBV genotypes South West region North West region
Tiko Buea Limbe Muyuka Muea Bafut Bamenda Bamessing
E 03 02 03 05 01 10 03 03
A 03 08 09 06 00 07 03 00
B 00 00 00 00 00 00 00 01
A/C 01 01 00 00 00 00 00 00
C/E 02 01 00 00 00 00 00 00
A/E 00 00 00 00 00 01 01 00
A/B 00 01 00 00 00 00 00 00
A/C 00 00 01 00 00 00 00 00
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source and circulating at low levels within this area. Like-
wise, mixed genotype A/E found only in Bamenda and 
neighbouring Bafut in the North West Region of Cam-
eroon may as well imply that this mixed genotype origi-
nated from the same individual residing in that area.
The HBV DNA level, which is directly proportional 
to the amount of HBV in the patient, is considered the 
gold standard for determining disease progression and 
has recently been shown to be the most useful predic-
tor of the development of cirrhosis and hepatocellular 
carcinoma (HCC) [24]. In our study, HBV genotype E 
was significantly associated with high mean viraemia 
and mean AST. This observation makes it increasingly 
obvious that heterogeneity in the global distribution of 
HBV genotypes may be responsible for differences in the 
progression, clinical outcomes of HBV infections and 
the possible response to vaccines and antiviral treatment 
as seen in some other studies [15]. However, genotype 
E which happens to be predominantly found in West 
Africa, has not been extensively studied in terms of its 
pathogenicity and virulence [20, 25].
HBV viral load and liver aminotransferase
The release of liver aminotransferase into blood circula-
tion following liver cell damage or lysis of hepatocytes 
is believed to be mostly associated with cell mediated 
immunity rather than the cytopathic effect of the virus 
[26]. This liver cell death may be either via apoptosis or 
via necrosis. Apoptosis in infected hepatocytes (orches-
trated by T-cytotoxic cells via the perforin/granzyme 
pathway) is characterized by little or no cell content 
spillage into the circulation (following death) since the 
apoptotic bodies are usually phagocytosed and inter-
nally destroyed by macrophages unlike in necrosis where 
the cells experience unfavourable conditions, swell and 
burst releasing their content into the circulation. [27]. 
With this in mind, one may expect to find more AST and 
ALT in circulation following necrosis rather than apop-
tosis. However, there is still a challenge in determining 
which modes of cell death predominate in various forms 
of liver disease and injury. Apoptosis and necrosis fre-
quently represent alternate outcomes of the same cellu-
lar pathways to cell death [28]. A statistically significant 
difference between the ALT and AST means of HBV 
infected cases and healthy controls justify aminotrans-
ferase elevation in circulation during HBV infection 
following liver damage as demonstrated by many other 
studies [29–31].
One may probably expect a patient with a high viral 
load to have a high number of HBV infected hepatocytes 
and as such more liver aminotransferase in circulation 
following the damage of these numerous infected cells. 
As observed in other studies [32], our study was very 
much in line with this theory as patients with abnormal 
(high) ALT and AST values showed significantly greater 
mean viral loads as compared to patients with normal 
ALT and AST values.
However, this identified relationship does not neces-
sarily justify the use of liver aminotransferases as single 
biomarkers for liver damage and/or disease progression 
as is done in Cameroon and other resource-limited set-
tings because some patients with normal ALT and AST 
also recorded high HBV viral loads. This implies that 
perhaps a good number of the cells died via apoptosis 
and as such, did not spill AST and ALT into the circula-
tion. A liver tissue biopsy can as well reveal inflamma-
tion in such cases [27]. Looking at the different phases 
of chronic Hepatitis B infection, one could either group 
Table 5 Comparison of mean viral load in the age groups, 
sex, HBV genotypes, ALT and AST levels
p values that show a statistically significant difference are in italics
SD standard deviation, AST aspartate aminotransferase, ALT alanine 
aminotransferase, AST (abnormal levels: M > 19, F > 16 IU/ml), ALT (abnormal 
levels: M > 22, F > 18 IU/ml)
a Others (B, B/C, A/B, A/E, C/E, A/C)
Variables Category N Mean ± SD (IU/ml) p value
Age (years) <30 39 107,555 ± 426,321 0.790
≥30 37 134,775 ± 459,749
Sex Male 27 275,634 ± 701,475 0.022
Female 49 35,493 ± 123,509
Genotypes A 36 26,855 ± 121,819 0.031
E 30 293,221 ± 685,464
Othersa 10 361 ± 340
AST Levels Normal 47 2259 ± 8036 0.002
Abnormal 29 312,936 ± 676,014
ALT Levels Normal 62 9743 ± 41,075 <0.001
Abnormal 14 612,659 ± 889,047
Table 6 Comparison of  mean ALT and  AST levels 
among the genotypes and viral load categories
p value that shows a statistically significant difference are in italics
SD- standard deviation, AST-aspartate aminotransferase, ALT alanine 
aminotransferase
a Others (B, B/C, A/B, A/E, C/E, A/C)
Genotypes Enzymes (mean ± SD, IU/ml)
AST p value ALT p value
A 16.36 ± 5.69 0.019 15.08 ± 5.91 0.176
E 19.74 ± 8.37 17.49 ± 9.10
others 13.69 ± 2.27 13.18 ± 4.56
Viral load category (IU/ml)
<20,000 15.97 ± 5.98 <0.001 14.29 ± 5.61 <0.001
≥20,000 24.34 ± 6.96 23.82 ± 10.01
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these particular patients under chronic immunotolerant 
phase (HBeAg positive, high HBV viral load and nor-
mal liver aminotransferase levels) or chronic immune 
active wild type HBV infection (HBsAg positive longer 
than 6  months, HBeAg positive, anti-HBe negative, 
high HBV viral load, elevated or normal liver ami-
notransferase levels). Both cases are characterized by 
the presence of HBeAg which is an indicator of active 
HBV replication and could imply high infectivity and 
transmission [33]. However, it becomes a bit challeng-
ing because some chronic HBV infections with active 
replication (elevated HBV DNA levels) are HBeAg nega-
tive (infection from precore mutant HBV strains) and 
this can be identified as active by the use of revised cut 
off values for ALT and HBV DNA levels as proven by 
some other studies [29–31]. Our study could not justify 
this because complete HBV serological profile test was 
not conducted on its participants to determine presence 
or absence of HBeAg and this is a key limitation to the 
study.
Conclusion
HBV genotype A and E are most common in the 
South  West and North  West regions of Cameroon 
respectively. Genotype E was significantly associated 
with higher mean viral load and mean AST levels. How-
ever, this study suggest that liver aminotransferase levels 
and HBV viral load may not always show a direct pro-
portional relationship as some patients had normal ami-
notransferase levels but high viral loads, which could be 
considered as active HBV infection. Therefore, viral load 
and liver aminotransferases measurement alongside HBV 
profile are recommended markers for HBV disease stag-
ing and progression.
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